This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
CLARITY
A Phase 3 randomised, double-masked, placebo-controlled study to investigate the safety and efficacy of oral Brepocitinib in adults with active, non-infectious intermediate-, posterior- and pan-uveitis.
Overview
Clarity is a research study aiming to learn more about the use of Brepocitinib for the treatment of active non-infectious intermediate/posterior/pan-uveitis, or NIU (non-infectious uveitis) for short.
NIU is the leading cause of preventable blindess and may be associated with other ocular or systemic inflammatory conditions – however, it is often idiopathic in nature. This condition causes your immune system to attack healthy tissue in your eye, causing inflammation. People with NIU experience eye pain, redness, light sensitivity and blurred vision.
Study treatment for this research study is Brepocitinib, which will be in the form of tablets – required to be taken up to 96 weeks with a four-week, follow-up safety period. As part of the study, suitable participants will be screened to determine their eligibility through various testing.
This study will require participants to attend Cerulea approximately on a monthly basis for the 24-month duration of the trial.
For further information about this study, please contact Cerulea on (03) 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Dr Jwu Jin Khong
Clarity is a research study aiming to learn more about the use of Brepocitinib for the treatment of active non-infectious intermediate/posterior/pan-uveitis, or NIU (non-infectious uveitis) for short.
NIU is the leading cause of preventable blindess and may be associated with other ocular or systemic inflammatory conditions – however, it is often idiopathic in nature. This condition causes your immune system to attack healthy tissue in your eye, causing inflammation. People with NIU experience eye pain, redness, light sensitivity and blurred vision.
Study treatment for this research study is Brepocitinib, which will be in the form of tablets – required to be taken up to 96 weeks with a four-week, follow-up safety period. As part of the study, suitable participants will be screened to determine their eligibility through various testing.
This study will require participants to attend Cerulea approximately on a monthly basis for the 24-month duration of the trial.
For further information about this study, please contact Cerulea on (03) 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.